| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Revenue | 74,835 | - |
| Total research and development | 87,736 | - |
| General and administrative | 32,052 | - |
| Other | -8,249 | - |
| Net loss | -36,704 | -23,256 |
| Depreciation and amortization | 2,343 | 1,580 |
| Share-based compensation expense | 18,591 | 12,862 |
| Foreign currency transaction loss | -319 | -149 |
| Accounts receivable | 3,977 | 13,230 |
| Prepaid expense and other assets | -4,088 | -4,145 |
| Right-of-use assets | -2,835 | -1,880 |
| Accounts payable | -1,616 | 3,429 |
| Accrued liabilities | -19,718 | -14,301 |
| Deferred revenue | -21,072 | -12,086 |
| Lease liabilities | -3,133 | -2,065 |
| Net cash used in operating activities | -58,044 | -40,893 |
| Acquisition of property and equipment | 318 | 137 |
| Net cash used in investing activities | -318 | -137 |
| Proceeds from exercise of stock options | 1,109 | 469 |
| Proceeds from the issuance of common stock under equity plans | 585 | - |
| Proceeds from debt | 15,000 | 15,000 |
| Payments on debt obligations | 15,000 | 15,000 |
| Net cash provided by financing activities | 1,694 | 469 |
| Net decrease in cash, cash equivalents and restricted cash | -56,668 | -40,561 |
| Cash and cash equivalents at beginning of period | 293,913 | - |
| Cash and cash equivalents at end of period | 237,245 | - |
Arcturus Therapeutics Holdings Inc. (ARCT)
Arcturus Therapeutics Holdings Inc. (ARCT)